The study, titled: "Modulating Default and Salience/Ventral Attention networks: Exploring the treatment effect of transcranial alternating current stimulation on chronic insomnia," evaluated the effects of four weeks of active treatment using Nexalin's DIFS technology versus sham devices in a randomized, double-blind, sham-controlled trial. According to the publication, patients in the active treatment group experienced a statistically significant reduction in Pittsburgh Sleep Quality Index (PSQI) scores from 13.8 to 7.7 (p < 0.001), while the sham group showed no significant change, with PSQI scores moving from 13.8 to 13.9 (p = 0.74).

The publication also reported that treatment was associated with measurable modulation of neural activity and functional connectivity in primary brain networks implicated in hyperarousal, emotional regulation, and self-referential processing, including the Default and Salience/Ventral Attention networks. The authors concluded that the findings provide insight into the potential mechanism of response by which Nexalin's proprietary frequency stimulation improves the functional health of the brain, which also improves sleep quality in individuals with chronic insomnia.